Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status

Patients on hemodialysis (HD) have a high burden of chronic inflammation induced associated with multiple comorbidities including poor nutritional status. Endotoxin (ET) is a Gram-negative bacterial cell wall component and a potent stimulus for innate immune system activation leading to the transcri...

Full description

Saved in:
Bibliographic Details
Main Authors: Natsuki Kubotera, Alexander J. Prokopienko, Adinoyi O. Garba, Amy Barton Pai
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:International Journal of Nephrology
Online Access:http://dx.doi.org/10.1155/2013/954956
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849305476197515264
author Natsuki Kubotera
Alexander J. Prokopienko
Adinoyi O. Garba
Amy Barton Pai
author_facet Natsuki Kubotera
Alexander J. Prokopienko
Adinoyi O. Garba
Amy Barton Pai
author_sort Natsuki Kubotera
collection DOAJ
description Patients on hemodialysis (HD) have a high burden of chronic inflammation induced associated with multiple comorbidities including poor nutritional status. Endotoxin (ET) is a Gram-negative bacterial cell wall component and a potent stimulus for innate immune system activation leading to the transcription of proinflammatory cytokines (e.g., IL-1, IL-6, and TNFα) that adversely affect protein metabolism and nutrition. Several cross-sectional observational studies have found that elevated serum ET concentrations in hemodialysis patients are associated with lower serum albumin, higher proinflammatory cytokine, and C-reactive protein concentrations. Possible sources of ET in the systemic circulation are bacterial translocation from the gastrointestinal tract and iron supplementation, potentially leading to intestinal bacterial overgrowth. Sevelamer is a nonabsorbable hydrogel approved for use as a phosphate binder in HD patients. Reductions in serum ET concentrations in hemodialysis patients have been observed with sevelamer therapy in observational studies and the few published interventional studies. Reduction of ET concentrations was associated with concomitant reductions in TNFα, IL-6, and CRP and improvement in serum albumin in the majority of these small studies. Additional studies are needed to evaluate the potential effects of sevelamer treatment on nutritional status in chronic kidney disease (CKD) patients with elevated ET.
format Article
id doaj-art-0a3ec01d6d1d43a797f2bc04918fe785
institution Kabale University
issn 2090-214X
2090-2158
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series International Journal of Nephrology
spelling doaj-art-0a3ec01d6d1d43a797f2bc04918fe7852025-08-20T03:55:27ZengWileyInternational Journal of Nephrology2090-214X2090-21582013-01-01201310.1155/2013/954956954956Endotoxin Binding by Sevelamer: Potential Impact on Nutritional StatusNatsuki Kubotera0Alexander J. Prokopienko1Adinoyi O. Garba2Amy Barton Pai3Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208, USADepartment of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208, USADepartment of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208, USADepartment of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208, USAPatients on hemodialysis (HD) have a high burden of chronic inflammation induced associated with multiple comorbidities including poor nutritional status. Endotoxin (ET) is a Gram-negative bacterial cell wall component and a potent stimulus for innate immune system activation leading to the transcription of proinflammatory cytokines (e.g., IL-1, IL-6, and TNFα) that adversely affect protein metabolism and nutrition. Several cross-sectional observational studies have found that elevated serum ET concentrations in hemodialysis patients are associated with lower serum albumin, higher proinflammatory cytokine, and C-reactive protein concentrations. Possible sources of ET in the systemic circulation are bacterial translocation from the gastrointestinal tract and iron supplementation, potentially leading to intestinal bacterial overgrowth. Sevelamer is a nonabsorbable hydrogel approved for use as a phosphate binder in HD patients. Reductions in serum ET concentrations in hemodialysis patients have been observed with sevelamer therapy in observational studies and the few published interventional studies. Reduction of ET concentrations was associated with concomitant reductions in TNFα, IL-6, and CRP and improvement in serum albumin in the majority of these small studies. Additional studies are needed to evaluate the potential effects of sevelamer treatment on nutritional status in chronic kidney disease (CKD) patients with elevated ET.http://dx.doi.org/10.1155/2013/954956
spellingShingle Natsuki Kubotera
Alexander J. Prokopienko
Adinoyi O. Garba
Amy Barton Pai
Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status
International Journal of Nephrology
title Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status
title_full Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status
title_fullStr Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status
title_full_unstemmed Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status
title_short Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status
title_sort endotoxin binding by sevelamer potential impact on nutritional status
url http://dx.doi.org/10.1155/2013/954956
work_keys_str_mv AT natsukikubotera endotoxinbindingbysevelamerpotentialimpactonnutritionalstatus
AT alexanderjprokopienko endotoxinbindingbysevelamerpotentialimpactonnutritionalstatus
AT adinoyiogarba endotoxinbindingbysevelamerpotentialimpactonnutritionalstatus
AT amybartonpai endotoxinbindingbysevelamerpotentialimpactonnutritionalstatus